ENG/中
老虎證券
行情
交易
收费
优惠与活动
帮助
TigerAI
专栏
关于
登入
立即註冊
Toggle
美股
詳情
本頁面由Tiger Trade Technology Pte. Ltd.提供服務
OncoMed Pharmaceuticals, Inc.
0.8900
0.0000
成交量：
- -
成交額：
- -
市值：
3,443.42萬
市盈率：
-4.22
高：
0.8900
開：
0.8900
低：
0.8900
收：
0.8900
52周最高：
3.35
52周最低：
0.5467
股本：
3,869.01萬
流通股本：
2,608.64萬
量比：
- -
換手率：
- -
股息：
- -
股息率：
- -
每股收益(TTM):
-0.2107
每股收益(LYR):
-0.2107
淨資產收益率：
--
總資產收益率：
--
市淨率：
0.71
市盈率(LYR):
-4.22
資料載入中...
總覽
公司
新聞資訊
公告
公司資料
公司名字：
OncoMed Pharmaceuticals, Inc.
交易所：
NASDAQ
成立時間：
- -
員工人數：
- -
公司地址：
- -
官網：
http://www.oncomed.com
郵編：
- -
電話：
- -
傳真：
- -
簡介：
Oncomed Pharmaceuticals, Inc.作為一家臨床階段的生物技術公司於2004年7月在特拉華州成立。公司致力於發現和開發對抗腫瘤干細胞的類單克隆抗體藥物。公司的業務和工作地點位於加利福尼亞州紅木城。其候選產品的目標是干細胞自我更新和通過阻斷腫瘤干細胞和大部分腫瘤細胞，以驅動細胞向非致瘤性狀態分化。公司認為，其候選產品不同於目前的化療，有顯著影響癌症治療與臨床結果的可能。
{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"澳洲华人首选美澳港股一站式交易平台 | 老虎证券","description":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","keywords":"老虎证券,老虎证券澳洲,老虎证券股票,老虎证券开户,老虎证券app,tigertrade老虎证券,股票,asx美股,炒股,券商,澳洲股票交易,澳大利亚炒股","social":{"ogDescription":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/OMED/company"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental","symbol":"OMED","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OMED\",,,,,undefined,":{"symbol":"OMED","market":"US","secType":"STK","nameCN":"OncoMed Pharmaceuticals, Inc.","latestPrice":0.89,"timestamp":1557432000000,"preClose":0.89,"halted":3,"volume":0,"delay":0,"changeRate":0,"floatShares":26086382,"shares":38690089,"eps":-0.210727,"marketStatus":"停牌","change":0,"latestTime":"05-09 16:00:00 EDT","open":0.89,"high":0.89,"low":0.89,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.210727,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1771837200000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1374120000000,"exchange":"NASDAQ","adjPreClose":0.89,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OMED\",,,,,undefined,":{"symbol":"OMED","floatShares":26086382,"roa":"--","roe":"--","lyrEps":-0.210727,"shares":38690089,"dividePrice":0,"high":0.89,"amplitude":0,"preClose":0.89,"low":0.89,"week52Low":0.5467,"pbRate":"0.71","week52High":3.35,"institutionHeld":0,"latestPrice":0.89,"eps":-0.210727,"divideRate":0,"volume":0,"delay":0,"ttmEps":-0.210727,"open":0.89,"prevYearClose":0.89},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/OMED\",params:#limit:5,,,undefined,":[{"market":"US","date":"2019-03-07","symbol":"OMED","fiscalQuarterEnding":"2018/12","expectedEps":-0.22,"name":null,"time":"","type":"earning","dateTimestamp":1551934800000,"reportTimeType":"","actualEps":-0.07},{"market":"US","date":"2018-11-01","symbol":"OMED","fiscalQuarterEnding":"2018/09","expectedEps":-0.2,"name":null,"time":"","type":"earning","dateTimestamp":1541044800000,"reportTimeType":"","actualEps":0.16},{"market":"US","date":"2018-08-02","symbol":"OMED","fiscalQuarterEnding":"2018/06","expectedEps":-0.23,"name":null,"time":"","type":"earning","dateTimestamp":1533182400000,"reportTimeType":"","actualEps":-0.1},{"market":"US","date":"2018-05-08","symbol":"OMED","fiscalQuarterEnding":"2018/03","expectedEps":-0.25,"name":null,"time":"盤後","type":"earning","dateTimestamp":1525752000000,"reportTimeType":"post","actualEps":-0.15},{"market":"US","date":"2018-03-08","symbol":"OMED","fiscalQuarterEnding":"2017/12","expectedEps":-0.31,"name":null,"time":"盤後","type":"earning","dateTimestamp":1520485200000,"reportTimeType":"post","actualEps":0.25}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"OMED\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"OMED\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.oncomed.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":0.0113},{"period":"1month","weight":0.0059},{"period":"3month","weight":0.0461},{"period":"6month","weight":0.0684},{"period":"1year","weight":0.1295},{"period":"ytd","weight":0.011}],"compareStock":{"symbol":"SPY","name":"標普500ETF"},"description":"Oncomed Pharmaceuticals, Inc.作為一家臨床階段的生物技術公司於2004年7月在特拉華州成立。公司致力於發現和開發對抗腫瘤干細胞的類單克隆抗體藥物。公司的業務和工作地點位於加利福尼亞州紅木城。其候選產品的目標是干細胞自我更新和通過阻斷腫瘤干細胞和大部分腫瘤細胞，以驅動細胞向非致瘤性狀態分化。公司認為，其候選產品不同於目前的化療，有顯著影響癌症治療與臨床結果的可能。","exchange":"NASDAQ","name":"OncoMed Pharmaceuticals, Inc.","nameEN":"OncoMed Pharmaceuticals"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"OMED\",market:\"US\",,,undefined,":null}}